Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Dec 14:17:100286.
doi: 10.1016/j.lrr.2021.100286. eCollection 2022.

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen

Nikeeta Mandhan  1 , Farah Yassine  2 , Ke Li  3 , Talha Badar  2
Affiliations
Case Reports

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen

Nikeeta Mandhan et al. Leuk Res Rep. .

Abstract

Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide with, or follow the diagnosis of a myeloid disorder. MS treatment is controversial, but AML induction like regimens is usually recommended. We present an unusual case of de novo TP53 mutated MDS/MPN overlap with bladder MS. Due to the high-risk nature of the disease, the patient was induced with decitabine and venetoclax combination therapy, resulting in complete remission. The response was further consolidated by an allogeneic hematopoietic stem cell transplantation.

Keywords: Decitabine-venetoclax; Hematopoietic stem cell transplantation; MDS/MPN overlap; Myeloid sarcoma; TP53 mutation.

PubMed Disclaimer

Conflict of interest statement

Talha Badar reports receiving honoraria from Pfizer-hematology and Oncology. Received Mayo Clinic Cancer Center Support Grant (CCSG) (P30 CA015083)

Figures

Fig 1
Fig. 1
Pathological findings of the urinary bladder mass biopsy: (a) Fragments of bladder mucosa and submucosa with multifocal cellular infiltrate composed of histiocytes, eosinophils, and neutrophils (hematoxylin-eosin staining; magnification 40x); Immunochemistry showing positive staining for (b) CD68 marking abundant histiocytes (magnification 20x) and (c) myeloperoxidase highlighting myeloid differentiation in neoplastic cells (magnification 20x).
See this image and copyright information in PMC

References

    1. Shahin O.A., Ravandi F. Myeloid sarcoma. Curr. Opin. Hematol. 2020;27(2):88–94. - PubMed
    1. Almond L.M., Charalampakis M., Ford S.J., Gourevitch D., Desai A. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin. Lymphoma Myeloma Leuk. 2017;17(5):263–267. - PubMed
    1. Shallis R.M., Gale R.P., Lazarus H.M., Roberts K.B., Xu M.L., Seropian S.E., Gore S.D., Podoltsev N.A. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. 2021;47 - PubMed
    1. Kaur V., Swami A., Alapat D., Abdallah A.O., Motwani P., Hutchins L.F., Jethava Y. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018;23(1):17–24. - PubMed
    1. Ganzel C., Manola J., Douer D., Rowe J.M., Fernandez H.F., Paietta E.M., Litzow M.R., Lee J.W., Luger S.M., Lazarus H.M., Cripe L.D., Wiernik P.H., Tallman M.S. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN cancer research group trials, 1980-2008. J. Clin. Oncol. 2016;34(29):3544–3553. - PMC - PubMed

Publication types